CTMX CytomX Therapeutics, Inc. gains 32% Dec 30, 2019
Preclinical biotech developing tumor-activated cancer immunotherapies.http://www.priceseries.com/trade/CTMX-CytomX-Therapeutics-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2019120620191230.html